Anthony Buisson
- CHU de Clermont-Ferrand, Service d'Hépatogastroentérologie · University Hospital, Clermont-Ferrand · cl
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Anthony Buisson as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 04:21 UTC. Open this list on ClinicalTrials.gov
- N/ANCT07653750 · Study on Variation of Serum and Fecal Biomarkers After Treatment to Predict Mucosal Healing in Patients With Ulcerative ColitisUniversity Hospital, Clermont-Ferrand · terminated · Moderate to Severe Ulcerative Colitis · principal investigator
- Ph4NCT07576452 · FirST Lines of Biologics in pAtients With ulceRaTivE Colitis: a Randomised Controlled TrialUniversity Hospital, Clermont-Ferrand · not yet recruiting · Ulcerative Colitis (UC) · principal investigator
- N/ANCT07564609 · the REMONO-CD and the REMONO-UC StudiesUniversity Hospital, Clermont-Ferrand · enrolling by invitation · Crohn Disease (CD), Ulcerative Colitis (UC) · principal investigator
- N/ANCT07471438 · Concordance Between Inflammatory Activity Assessed by Enteric MRI With and Without Intestinal Distension Product in Patients With Ileal Crohn's Disease.University Hospital, Clermont-Ferrand · recruiting · Crohn Disease (CD) · principal investigator
- N/ANCT07308067 · Kinetics of Transmural Healing in Patients With Crohns Disease Treated With Risankizumab (SKYRIZI®)University Hospital, Clermont-Ferrand · active not recruiting · Crohn Disease (CD) · principal investigator
- Ph4NCT07292012 · Efficacy of MIrikizumab to Achieve Transmural Healing in patiENTs With Crohn's DiseaseGroupe d'Etude Therapeutique des Affections Inflammatoires Digestives · recruiting · Crohn Disease (CD) · principal investigator
- N/ANCT06972901 · Evaluation of Therapeutic Strategy to Prevent Crohn's Disease Endoscopic poSToperatIve recurreNce Based on earlY Dosage of Faecal CalprotectinUniversity Hospital, Clermont-Ferrand · recruiting · Crohn Disease (CD), Ileocolic Resection, Post-endoscopic Operative Reccurence · principal investigator
- N/ANCT03404557 · Proteomic Analysis of Crohn's Disease Macrophages in Response or Not to AIECUniversity Hospital, Clermont-Ferrand · completed · Crohn's Disease, Ulcerative Colitis · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 04:21 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 04:21 UTC. The ranking covers the 200 most relevant of 15 PubMed records, and a shared surname and initials can bring in a namesake. All 15 on PubMed
- 260 citationsRCR 13.6
- Clinical outcome of breast cancer in carriers of BRCA1 and BRCA2 mutations according to molecular subtypes.Sci Rep · 202083 citationsRCR 3.5
- Monitoring a Combination of Calprotectin and Infliximab Identifies Patients With Mucosal Healing of Crohn's Disease.Clin Gastroenterol Hepatol · 202070 citationsRCR 4.2
- 52 citationsRCR 5.6
- Oral Curcumin No More Effective Than Placebo in Preventing Recurrence of Crohn's Disease After Surgery in a Randomized Controlled Trial.Clin Gastroenterol Hepatol · 202048 citationsRCR 3.4
- Long-term effectiveness and acceptability of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel disease treated with intensified doses: The REMSWITCH-LT study.Aliment Pharmacol Ther · 202435 citationsRCR 6.0
- Location but Not Severity of Endoscopic Lesions Influences Endoscopic Remission Rates in Crohn's Disease: A Post Hoc Analysis of TAILORIX.Am J Gastroenterol · 202129 citationsRCR 1.8
- Safety, pharmacokinetic, and pharmacodynamic study of sibofimloc, a novel FimH blocker in patients with active Crohn's disease.J Gastroenterol Hepatol · 202225 citationsRCR 1.9
- Steroid-Free Deep Remission at One Year Does Not Prevent Crohn's Disease Progression: Long-Term Data From the TAILORIX Trial.Clin Gastroenterol Hepatol · 202222 citationsRCR 1.7
- Variation of faecal calprotectin level within the first three months after bowel resection is predictive of endoscopic postoperative recurrence in Crohn's disease.Dig Liver Dis · 202019 citationsRCR 1.3